Cash Flow Statement
Growth Metrics

Harvard Bioscience (HBIO) Non-Current Deferred Tax Liability (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Non-Current Deferred Tax Liability for 16 consecutive years, with $317000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 55.35% to $317000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $317000.0 through Dec 2025, down 55.35% year-over-year, with the annual reading at $317000.0 for FY2025, 55.35% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $317000.0 at Harvard Bioscience, down from $733000.0 in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $2.4 million in Q2 2022, with the low at $317000.0 in Q4 2025.
  • Average Non-Current Deferred Tax Liability over 5 years is $1.0 million, with a median of $749000.0 recorded in 2024.
  • The sharpest move saw Non-Current Deferred Tax Liability surged 54.39% in 2022, then crashed 72.52% in 2023.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $1.6 million in 2021, then crashed by 62.13% to $590000.0 in 2022, then soared by 31.53% to $776000.0 in 2023, then fell by 8.51% to $710000.0 in 2024, then crashed by 55.35% to $317000.0 in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $317000.0, $733000.0, and $734000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.